What is the 13F Pro Quality Score for OGN?

13F Pro ranks Organon & Co. (OGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OGN's current score at https://13fpro.ai/research/OGN (free sign-up required for the full ranking).

Where does 13F Pro source OGN data?

All Organon & Co. fundamentals and ownership data come directly from SEC EDGAR. Organon & Co. files with the SEC under CIK 1821825. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OGN in?

Organon & Co. (OGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OGN research updated on 13F Pro?

OGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Organon & Co.(OGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1821825 OGN stock profile & AI dashboard →

13F Pro Quality Score

55.1/100

Rank #1,176 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

29.3/100

Profitability

53.1/100

Balance Sheet

65.8/100

Earnings Quality

25.8/100

Free Cash Flow

63.8/100

Institutional Flow

63.0/100

Revenue Scale

81.3/100

Dilution Risk

51.6/100

OGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Organon & Co. (OGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OGN at 55.1/100 on a 32-signal composite quality model, placing it at rank #1,176 of 2,879 stocks — the top half of the AI-ranked universe. OGN scores in the top quartile across revenue scale (81.3). Areas of concern include earnings quality (25.8) and revenue growth (29.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Organon & Co. reports quarterly revenue of $1.5B, net income of $146.0M, free cash flow of $188.0M. Top institutional holders of OGN by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. OGN trades on the NYSE exchange and files with the SEC under CIK 1821825. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Organon & Co. directly from SEC EDGAR. Organon & Co.'s 13F Pro composite quality score has ranged between 8 and 65 since 2022, currently 55.1 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.

Revenue

Q1 2026

$1.5B

Net Income

Q1 2026

$146.0M

Free Cash Flow

Q1 2026

$188.0M

ROIC

Q1 2026

2.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-0.8% YoY

$6.22BFY 2025

FY20 $6.53BFY21 $6.30BFY23 $6.26BFY25 $6.22B

Net Income

-81.7% YoY

$187.0MFY 2025

FY20 $2.16BFY21 $1.35BFY23 $1.02BFY25 $187.0M

EPS (Diluted)

-82.0% YoY

$0.72FY 2025

FY20 $8.52FY21 $5.31FY23 $3.99FY25 $0.72

Total Assets

+6.7% YoY

$12.87BFY 2025

FY20 $10.11BFY21 $10.68BFY23 $12.06BFY25 $12.87B

Total Debt

-1.2% YoY

$8.66BFY 2025

FY20 $0.00FY21 $9.14BFY23 $8.77BFY25 $8.66B

Op. Cash Flow

-12.4% YoY

$700.0MFY 2025

FY20 —FY21 —FY23 $799.0MFY25 $700.0M

Metric	FY 2025	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$6.22B -0.8%	$6.26B -0.7%	$6.30B -3.5%	$6.53B -16.0%	$7.78B	—
Net Income	$187.0M -81.7%	$1.02B -24.3%	$1.35B -37.5%	$2.16B -32.9%	$3.22B	—
EPS (Diluted)	$0.72 -82.0%	$3.99 -24.9%	$5.31 -37.7%	$8.52 -32.9%	$12.69	—
Total Assets	$12.87B +6.7%	$12.06B +12.9%	$10.68B +5.7%	$10.11B	—	—
Total Debt	$8.66B -1.2%	$8.77B -4.1%	$9.14B	$0.00	—	—
Operating Cash Flow	$700.0M -12.4%	$799.0M	—	—	—	—

AI Insight: OGN Financial Trends

Revenue declined 9% over two years to $1,460M in Q1 2026 while debt remains elevated at $8,585M despite recent deleveraging.

• Revenue decreased from $1,607M in Q2 2024 to $1,460M in Q1 2026, a 9% decline over eight quarters.

• Equity strengthened significantly from $144M in Q2 2024 to $903M in Q1 2026, a 527% increase.

• Total debt reduced from peak of $9,011M in Q2 2025 to $8,585M in Q1 2026.

⚠ Net income turned sharply negative to -$205M in Q4 2025 after consistent profitability in prior quarters.

⚠ Operating cash flow remains volatile, ranging from $75M to $390M across recent quarters with no clear trend.

AI Insight: OGN Ratio Trends

Organon recovered strongly in Q1 2026 with 14.6% operating margin after a steep Q4 2025 loss, but profitability remains well below 2024 levels.

• Operating margin plunged from 15.2% in Q3 2025 to -9.8% in Q4 2025, then rebounded to 14.6% in Q1 2026.

• ROIC declined from 10.7% in Q2 2024 to 9.0% in Q1 2026, with volatility including negative -6.3% in Q4 2025.

• Debt-to-equity ratio improved from 18.86 in Q4 2024 to 9.51 in Q1 2026, indicating deleveraging progress.

⚠ Q4 2025 losses created significant earnings volatility with -13.6% net margin and -109.0% ROE requiring monitoring for recurrence.

⚠ TTM operating margin of 8.7% significantly trails recent quarterly performance, suggesting potential earnings normalization challenges.

Get alerted when OGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Organon & Co. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OGN

BlackRock, Inc.
$190.0M31,717,028 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$130.9M21,846,036 sh
VANGUARD CAPITAL MANAGEMENT LLC
$70.3M11,737,018 sh
STATE STREET CORP
$59.6M9,956,774 sh
EverSource Wealth Advisors, LLC
$41.8M126,291 sh
MILLENNIUM MANAGEMENT LLC
$40.6M6,781,535 sh
KAHN BROTHERS GROUP INC
$33.2M5,536,993 sh
CANADA PENSION PLAN INVESTMENT BOARD
$30.0M5,011,100 sh
GEODE CAPITAL MANAGEMENT, LLC
$28.5M4,759,337 sh
PRIVATE MANAGEMENT GROUP INC
$26.2M4,374,108 sh

Fund	Value	Shares
BlackRock, Inc.	$190.0M	31,717,028
VANGUARD PORTFOLIO MANAGEMENT LLC	$130.9M	21,846,036
VANGUARD CAPITAL MANAGEMENT LLC	$70.3M	11,737,018
STATE STREET CORP	$59.6M	9,956,774
EverSource Wealth Advisors, LLC	$41.8M	126,291
MILLENNIUM MANAGEMENT LLC	$40.6M	6,781,535
KAHN BROTHERS GROUP INC	$33.2M	5,536,993
CANADA PENSION PLAN INVESTMENT BOARD	$30.0M	5,011,100
GEODE CAPITAL MANAGEMENT, LLC	$28.5M	4,759,337
PRIVATE MANAGEMENT GROUP INC	$26.2M	4,374,108

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OGN on your watchlist

Track score changes the day Organon & Co. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OGN a good stock to buy?

13F Pro's AI-powered analysis of Organon & Co. (OGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OGN are available on the OGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Organon & Co.'s investment landscape.